Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab

Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the short-term outcomes for patients who received int...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Sakanishi Y, Usui-Ouchi A, Tamaki K, Mashimo K, Ito R, Ebihara N
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2017
Sujets:	aflibercept ranibizumab switch branch retinal vein occlusion macular edema Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/ad72d1dea1af4a47b0913630a94c2fa5
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:ad72d1dea1af4a47b0913630a94c2fa5
record_format	dspace
spelling	oai:doaj.org-article:ad72d1dea1af4a47b0913630a94c2fa52021-12-02T04:41:58ZShort-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab1177-5483https://doaj.org/article/ad72d1dea1af4a47b0913630a94c2fa52017-05-01T00:00:00Zhttps://www.dovepress.com/short-term-outcomes-in-patients-with-branch-retinal-vein-occlusion-who-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). Patients and methods: Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group. Patient outcomes were examined at 1 week and 1 month postinjection. Results: Both groups comprised 27 eyes from 27 patients. There was a significant decrease in central macular thickness (CMT) at 1 week and 1 month postinjection in both groups. There was also a significant improvement in best-corrected visual acuity (BCVA) at 1 week and 1 month postinjection in the treatment-naïve group and 1 month in the switching group. Younger age was associated with a good BCVA at 1 month postinjection in the switching group, and the absence of epiretinal membrane was associated with a reduction in CMT at 1 month postinjection in the switching group. Conclusion: IVA is temporarily effective for treating ME due to BRVO regardless of a history of IVR use. Keywords: BRVO, IVR, IVA, switch Sakanishi YUsui-Ouchi ATamaki KMashimo KIto REbihara NDove Medical Pressarticleafliberceptranibizumabswitchbranch retinal vein occlusionmacular edemaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 829-834 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	aflibercept ranibizumab switch branch retinal vein occlusion macular edema Ophthalmology RE1-994
spellingShingle	aflibercept ranibizumab switch branch retinal vein occlusion macular edema Ophthalmology RE1-994 Sakanishi Y Usui-Ouchi A Tamaki K Mashimo K Ito R Ebihara N Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
description	Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). Patients and methods: Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group. Patient outcomes were examined at 1 week and 1 month postinjection. Results: Both groups comprised 27 eyes from 27 patients. There was a significant decrease in central macular thickness (CMT) at 1 week and 1 month postinjection in both groups. There was also a significant improvement in best-corrected visual acuity (BCVA) at 1 week and 1 month postinjection in the treatment-naïve group and 1 month in the switching group. Younger age was associated with a good BCVA at 1 month postinjection in the switching group, and the absence of epiretinal membrane was associated with a reduction in CMT at 1 month postinjection in the switching group. Conclusion: IVA is temporarily effective for treating ME due to BRVO regardless of a history of IVR use. Keywords: BRVO, IVR, IVA, switch
format	article
author	Sakanishi Y Usui-Ouchi A Tamaki K Mashimo K Ito R Ebihara N
author_facet	Sakanishi Y Usui-Ouchi A Tamaki K Mashimo K Ito R Ebihara N
author_sort	Sakanishi Y
title	Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
title_short	Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
title_full	Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
title_fullStr	Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
title_full_unstemmed	Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
title_sort	short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/ad72d1dea1af4a47b0913630a94c2fa5
work_keys_str_mv	AT sakanishiy shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT usuiouchia shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT tamakik shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT mashimok shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT itor shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab AT ebiharan shorttermoutcomesinpatientswithbranchretinalveinocclusionwhoreceivedintravitrealafliberceptwithorwithoutintravitrealranibizumab
_version_	1718401143777787904

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab

Documents similaires